Edwards Lifesciences Co. (NYSE:EW) Holdings Lowered by Flagship Harbor Advisors LLC

Flagship Harbor Advisors LLC lowered its stake in Edwards Lifesciences Co. (NYSE:EW) by 14.7% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 11,213 shares of the medical research company’s stock after selling 1,932 shares during the quarter. Flagship Harbor Advisors LLC’s holdings in Edwards Lifesciences were worth $830,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Wellington Management Group LLP increased its position in shares of Edwards Lifesciences by 86.3% in the third quarter. Wellington Management Group LLP now owns 31,532,725 shares of the medical research company’s stock worth $2,080,845,000 after acquiring an additional 14,610,123 shares in the last quarter. State Street Corp lifted its holdings in shares of Edwards Lifesciences by 1.0% in the third quarter. State Street Corp now owns 26,265,633 shares of the medical research company’s stock valued at $1,733,270,000 after purchasing an additional 256,538 shares in the last quarter. Geode Capital Management LLC boosted its position in shares of Edwards Lifesciences by 2.2% in the third quarter. Geode Capital Management LLC now owns 13,521,147 shares of the medical research company’s stock worth $889,050,000 after buying an additional 284,918 shares during the period. Fisher Asset Management LLC grew its holdings in shares of Edwards Lifesciences by 9.8% during the third quarter. Fisher Asset Management LLC now owns 9,078,311 shares of the medical research company’s stock valued at $599,078,000 after buying an additional 806,705 shares in the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its position in Edwards Lifesciences by 1.0% during the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 6,005,789 shares of the medical research company’s stock valued at $396,322,000 after buying an additional 61,275 shares during the period. Institutional investors and hedge funds own 79.46% of the company’s stock.

Insider Activity

In other news, insider Larry L. Wood sold 25,000 shares of Edwards Lifesciences stock in a transaction that occurred on Tuesday, November 5th. The shares were sold at an average price of $65.91, for a total value of $1,647,750.00. Following the completion of the transaction, the insider now owns 198,526 shares in the company, valued at approximately $13,084,848.66. The trade was a 11.18 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, VP Daniel J. Lippis sold 500 shares of the stock in a transaction that occurred on Thursday, January 16th. The stock was sold at an average price of $68.76, for a total value of $34,380.00. Following the sale, the vice president now owns 23,189 shares in the company, valued at approximately $1,594,475.64. This trade represents a 2.11 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 33,000 shares of company stock worth $2,195,180. Company insiders own 1.29% of the company’s stock.

Edwards Lifesciences Price Performance

Shares of NYSE:EW opened at $69.21 on Tuesday. The company has a quick ratio of 2.89, a current ratio of 3.46 and a debt-to-equity ratio of 0.06. The business has a 50 day moving average price of $72.33 and a 200 day moving average price of $70.36. The company has a market cap of $40.82 billion, a price-to-earnings ratio of 9.99, a PEG ratio of 3.54 and a beta of 1.11. Edwards Lifesciences Co. has a twelve month low of $58.93 and a twelve month high of $96.12.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on EW. Stifel Nicolaus lifted their target price on Edwards Lifesciences from $70.00 to $75.00 and gave the company a “hold” rating in a research note on Thursday, December 5th. JPMorgan Chase & Co. boosted their price objective on shares of Edwards Lifesciences from $72.00 to $78.00 and gave the company a “neutral” rating in a research report on Friday, October 25th. Truist Financial reiterated a “hold” rating and issued a $78.00 target price (up previously from $70.00) on shares of Edwards Lifesciences in a research report on Thursday, December 5th. Canaccord Genuity Group boosted their price target on shares of Edwards Lifesciences from $63.00 to $68.00 and gave the company a “hold” rating in a report on Thursday, December 5th. Finally, Evercore ISI cut their price objective on Edwards Lifesciences from $76.00 to $70.00 and set an “in-line” rating for the company in a report on Tuesday, October 1st. One research analyst has rated the stock with a sell rating, fifteen have issued a hold rating and eleven have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $78.48.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.